Tonix Pharmaceuticals Holding Corp. (TNXP)
NASDAQ: TNXPHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
TNXP stock chart
Technical analysisKey statistics
All statistics- Market cap
- $46.25M
- EPS (TTM)
- -$12.39
- Dividend yield
- None
- 52-week range
- 2.30 – 20.56
- Day range
- 2.30 – 2.63
- Volume / Avg
- 1.26M / 838.83K
- Beta
- —
- Shares outstanding
- 19.43M
52-week range
TNXP stock today
Shares of Tonix Pharmaceuticals (TNXP) finished lower on Nov 20 at $2.38, a drop of 6.67% or $0.17 per share, versus the S&P 500's 3.70% decline. At this level, TNXP sits near the bottom of its 52-week range of $2.30 to $20.56: 88.4% below the high, set on Dec 12, 2025 and 3.5% above the low. TNXP is down 84.8% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 85.2%.
Tonix Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$12.39), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Tonix Pharmaceuticals
Company profileTonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia. It also markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Seth Lederman M.D.
- Headquarters
- Berkeley Heights, NJ
- Employees
- 142
- Website
- tonixpharma.com
Financial highlights
Full financialsIn fiscal 2025, Tonix Pharmaceuticals generated $13.1 million in revenue, up 29.8% from fiscal 2024, its 2nd consecutive year of revenue growth. Tonix Pharmaceuticals reported a net loss of $124.0 million, compared with a loss of $130.0 million a year earlier. Gross margin was 49.3% (up from 23.1%) and operating margin -959.1%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $13.11M | $10.09M | $7.77M | — | — |
| Growth | +29.85% | +29.94% | — | — | — |
| Net income | $-124.02M | $-130.04M | $-116.66M | $-110.22M | $-92.29M |
| EPS (diluted) | $-14.57 | $-176.60 | $-14,720.25 | $-20.01 | $-8.10 |
Analyst forecast
ForecastConsensus (3 analysts)
strong_buy
Avg. price target
$44.50+1769.75%
- Strong buy 0
- Buy 3
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 9, 2026
- EPS actual vs est.
- $-2.89 vs $-2.51
- Surprise
- -15.14%
TNXP news
All TNXP news- Tonix Pharmaceuticals (TNXP) Q3 2026 Earnings Call TranscriptNasdaq
- Tonix Pharmaceuticals Holding Corp. Reports Third Quarter 2026 Financial ResultsNasdaq
- Tonix Pharmaceuticals Reports Third Quarter 2026 Financial Results and Operational HighlightsGlobeNewswire
- Tonix Pharmaceuticals to Present at Guggenheim’s 3rd Annual Healthcare Innovation ConferenceGlobeNewswire
- Tonix Pharmaceuticals Presented an Analysis of Phase 3 Data Demonstrating TONMYA® Improved Physical Symptoms and Functional Ability of Patients with Fibromyalgia at the IASP 2026 World Congress on PainGlobeNewswire
- Canaccord Genuity Initiates Coverage of Tonix Pharmaceuticals Holding with BuyNasdaq
- Tonix Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 9, 2026GlobeNewswire
- Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Europe 2026GlobeNewswire
Tonix Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| MISTMilestone Pharmaceuticals Inc. | 0.3711 | -7.06% | $46.20M | vs TNXP |
| HOWLWerewolf Therapeutics Inc. | 0.9466 | -3.97% | $46.00M | vs TNXP |
| RNXTRenovoRx Inc. | 0.942 | -10.29% | $45.45M | vs TNXP |
| VRCAVerrica Pharmaceuticals Inc. | 2.74 | -5.03% | $47.07M | vs TNXP |
| NMADNomad Power Solutions Inc. | 2.56 | +13.53% | $47.15M | vs TNXP |
| APLMApollomics Inc. Class A | 15.54 | -6.92% | $45.28M | vs TNXP |
| ONCYOncolytics Biotech Inc. | 0.3501 | -10.37% | $47.66M | vs TNXP |
| QUCYQuantum Cyber N.V. | 0.512 | -7.25% | $44.67M | vs TNXP |
Indexes, lists and sector
Tonix Pharmaceuticals stock FAQ
What is Tonix Pharmaceuticals's stock price today?
TNXP last traded at $2.38 as of Nov 20, 4:00 PM EST, down 6.67% on the day. Prices are delayed at least 15 minutes.
Does Tonix Pharmaceuticals pay a dividend?
No. Tonix Pharmaceuticals does not currently pay a regular cash dividend.
Who is Tonix Pharmaceuticals's CEO?
Dr. Seth Lederman M.D. is the chief executive officer of Tonix Pharmaceuticals Holding Corp., which has about 142 employees.
Has TNXP ever split its stock?
Yes. The most recent TNXP stock split was a 1-for-100 split on Feb 5, 2025, one of 8 splits on record.
What is the TNXP 52-week high?
The 52-week high for TNXP is $20.56 and the 52-week low is $2.30. The stock is currently 88.4% below its high.